Hologic is leveraging its software-defined imaging platform to deliver hospital-grade MRI precision at the bedside, positioning itself alongside VentriPoint Diagnostics, Butterfly Network and Hyperfine in a market projected to reach $70.92 billion by 2032. The company’s portable ultrasound systems now incorporate advanced deep-learning algorithms for automated lesion detection and volumetric analysis, reducing scan times by up to 30% and requiring 40% less technician intervention. With the CMS ACCESS Model set to launch in July 2026—offering outcome-based reimbursement incentives—Hologic expects a 25% year-over-year increase in point-of-care deployments across outpatient clinics and mobile health units.

In response to a documented decline in routine Pap and HPV screening rates—down from 83% five years ago to an estimated 77% last year—Hologic has introduced ‘Ultimate Defense,’ a nationwide public health initiative designed to drive awareness of cervical cancer prevention. The campaign partners with 120 community health centers and deploys targeted digital outreach, aiming to increase screening uptake by 15% over the next 12 months. Hologic is supplying over 500,000 test kits to underserved regions and sponsoring continuing-education webinars for 2,000 clinicians to reinforce best practices in specimen collection and patient follow-up.

Hologic will report financial results for the first quarter of fiscal 2026 on Thursday, January 29, after market close. In light of the pending acquisition by Blackstone and TPG, the company will forgo a quarterly conference call and will not provide forward-looking financial guidance. Investors will receive a detailed earnings release outlining revenue performance across diagnostics, breast health and surgical divisions, as well as updates on integration progress for recently acquired molecular diagnostics assets.